Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.54 USD
+0.02 (0.57%)
Updated May 28, 2024 04:00 PM ET
After-Market: $3.53 -0.01 (-0.28%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 421 - 432 ( 432 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Technology Found to Rapidly Produce Durable iPSCs, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Improved Safety with ProHema, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Improved Safety with ProHema, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan. 20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3:13 EPS: New Formulation Ready for the Clinic in H1:14, Two Wnt7a Leads Picked for IND-Enabling Studies, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage With an OUTPERFORM Rating and $14 Price Target; Fated to Create Better Stem Cells
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D